A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules.
This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally advanced, metastatic solid tumors disease.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Alison Johnson
- Beverly Drucker, MD, PhD
- David Witt, MD
- Emily Collier, MD
- Emily Kopas, APRN, OCN
- Francine Foss, MD
- Harold Tara Jr, MD
- Iris Isufi, MD
- James Vredenburgh, MD
- Jose Morales-Marin
- Justin Persico, MD
- Karishma Mehra, MBBS
- Kathleen Fenn, MD
- Kayla Martello
- Larisa Fleysher
- Laura Sabourin
- Leena Rahmat
- M. Sung Lee, MD
- Madeline Santiago
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Nicholas Blondin, MD
- Noffar Bar, MD
- Osarugue Otasowie
- Pawan Karanam, MD
- Renee Moye
- Stuart Seropian, MD
- Sudhanshu Mulay, MD
- Syed Ali
- Vidya Kesavan
- Zia Rahman, MD
- Last Updated11/14/2024
- Study HIC#2000034567